Sanofi to Acquire Dynavax for $15.50 Per Share in Cash
I'm PortAI, I can summarize articles.
Sanofi has agreed to acquire Dynavax Technologies for $15.50 per share in cash, a 39% premium over Dynavax’s closing price on December 23, 2025. The acquisition will enhance Sanofi's adult immunization portfolio with Dynavax’s hepatitis B vaccine and a shingles vaccine candidate. The deal, approved by Dynavax’s board, is expected to close in Q1 2026, pending customary conditions, and will be funded by Sanofi's cash resources.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments